stockportfolio.pro
Kura Oncology, Inc. (KURA)
Healthcare · Biotechnology · NasdaqGS
Kura Oncology, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $53.88M | $67.48M |
| Gross profit | — | — | — | — | — | — | — | — | $53.88M | $67.42M |
| Net income | $-27.56M | $-35.43M | $-60.45M | $-63.14M | $-89.63M | $-130.47M | $-135.84M | $-152.63M | $-173.98M | $-278.67M |
| Net margin | — | — | — | — | — | — | — | — | -322.9% | -412.9% |
Source: Kura Oncology, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
Explore 19 years of Kura Oncology, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KURA in your portfolio →
Kura Oncology, Inc. financial history by metric
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology, Inc. — frequently asked questions
What is Kura Oncology, Inc.'s revenue?
Kura Oncology, Inc. (KURA) reported revenue of $67.48M for fiscal year 2025, up 25.2% from the prior year, according to its SEC filings.
Is Kura Oncology, Inc. profitable?
No — KURA reported a net loss of $-278.67M in fiscal 2025.
What is KURA's P/E ratio?
Kura Oncology, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Kura Oncology, Inc. have?
As of fiscal year 2025, KURA carried roughly $9.71M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kura Oncology, Inc.'s gross margin?
KURA's gross margin was 99.9% in fiscal 2025 — gross profit of $67.42M on revenue of $67.48M.
What is Kura Oncology, Inc.'s market cap?
Kura Oncology, Inc. (KURA) has a market capitalization of about $794.53M, based on the latest data in our nightly-refreshed cache.
When does Kura Oncology, Inc.'s fiscal year end?
KURA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Kura Oncology, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.